Published in J Antimicrob Chemother on October 11, 2013
Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev (2014) 2.26
A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother (2014) 1.48
The Pandemic H30 Subclone of Escherichia coli Sequence Type 131 Is Associated With Persistent Infections and Adverse Outcomes Independent From Its Multidrug Resistance and Associations With Compromised Hosts. Clin Infect Dis (2016) 0.95
Diversity of Multi-Drug Resistant Avian Pathogenic Escherichia coli (APEC) Causing Outbreaks of Colibacillosis in Broilers during 2012 in Spain. PLoS One (2015) 0.86
Rapid Identification of Rectal Multidrug-resistant Escherichia coli Before Transrectal Prostate Biopsy. Urology (2015) 0.79
Isolation and Characterization of Escherichia coli Sequence Type 131 and Other Antimicrobial-Resistant Gram-Negative Bacilli from Clinical Stool Samples from Veterans. Antimicrob Agents Chemother (2016) 0.79
Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: a systematic review and meta-analysis. BMJ Open (2016) 0.78
The role of Sequence Type (ST) 131 in adult community-onset non-ESBL-producing Escherichia coli bacteraemia. BMC Infect Dis (2014) 0.77
Epidemic Emergence in the United States of Escherichia coli Sequence Type 131-H30, 2000-2009. Antimicrob Agents Chemother (2017) 0.77
The Niche for Escherichia coli Sequence Type 131 Among Veterans: Urinary Tract Abnormalities and Long-Term Care Facilities. Open Forum Infect Dis (2016) 0.76
In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study. Infect Dis Ther (2016) 0.76
β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates. Antimicrob Agents Chemother (2015) 0.75
Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis (2006) 3.79
β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis (2011) 3.40
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med (2008) 3.23
Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol (2004) 3.20
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Interaction of plasmid and host quinolone resistance. J Antimicrob Chemother (2003) 3.13
Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis (2013) 3.06
qnr Gene nomenclature. Antimicrob Agents Chemother (2008) 2.81
Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis (2010) 2.76
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology (2007) 2.39
Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A (2014) 2.20
Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother (2003) 2.19
[Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas maltophilia]. Enferm Infecc Microbiol Clin (2006) 2.09
Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis (2009) 1.83
Knowledge and perceptions of junior and senior Spanish resident doctors about antibiotic use and resistance: results of a multicenter survey. Enferm Infecc Microbiol Clin (2012) 1.70
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
[Acinetobacter baumannii bacteremia: clinical and prognostic features]. Enferm Infecc Microbiol Clin (2003) 1.61
Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther (2008) 1.60
Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis (2008) 1.58
Assessing the influence of risk factors on rates and dynamics of peripheral vein phlebitis: an observational cohort study. Med Clin (Barc) (2012) 1.54
Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother (2003) 1.54
Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation (2011) 1.53
[Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)]. Enferm Infecc Microbiol Clin (2003) 1.53
Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort. Clin Infect Dis (2013) 1.52
Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother (2008) 1.51
Trends in AIDS and mortality in HIV-infected subjects with hemophilia from 1985 to 2003: the competing risks for death between AIDS and liver disease. J Acquir Immune Defic Syndr (2006) 1.50
Plasmid-mediated quinolone resistance: an update. J Infect Chemother (2010) 1.48
Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol (2004) 1.46
[Activity and penetration of linezolid and vancomycin against Staphylococcus epidermidis biofilms]. Enferm Infecc Microbiol Clin (2007) 1.43
[Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000)]. Enferm Infecc Microbiol Clin (2004) 1.41
Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother (2011) 1.41
Zinc eluted from siliconized latex urinary catheters decreases OprD expression, causing carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2003) 1.40
[Comparison of 3 methods for determining sensitivity to imipenem and meropenem in Acinetobacter baumannii with a carbapenem-heteroresistant phenotype]. Enferm Infecc Microbiol Clin (2008) 1.39
National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. J Antimicrob Chemother (2011) 1.38
Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production. Antimicrob Agents Chemother (2002) 1.37
[Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment]. Enferm Infecc Microbiol Clin (2005) 1.30
Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive "bundle" approach. Am J Infect Control (2009) 1.27
Use of positive blood cultures for direct identification and susceptibility testing with the vitek 2 system. J Clin Microbiol (2004) 1.25
Plasmid-mediated quinolone resistance. Expert Rev Anti Infect Ther (2008) 1.25
Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis (2005) 1.22
Four main virotypes among extended-spectrum-β-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: bacterial, epidemiological, and clinical characteristics. J Clin Microbiol (2013) 1.17
Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli. Clin Infect Dis (2009) 1.16
Progress on the development of rapid methods for antimicrobial susceptibility testing. J Antimicrob Chemother (2013) 1.14
Dalbavancin or oritavancin for skin infections. N Engl J Med (2014) 1.14
Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase. Antimicrob Agents Chemother (2005) 1.13
Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol (2010) 1.12
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. Antimicrob Agents Chemother (2008) 1.10
Diversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study. J Clin Microbiol (2010) 1.09
Acquisition and cross-transmission of Staphylococcus aureus in European intensive care units. Infect Control Hosp Epidemiol (2009) 1.07
Plasmid-mediated quinolone resistance in Australia. Microb Drug Resist (2006) 1.07
[Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)]. Enferm Infecc Microbiol Clin (2009) 1.07
Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS (2010) 1.04
Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother (2006) 1.03
Biofilm formation at the solid-liquid and air-liquid interfaces by Acinetobacter species. BMC Res Notes (2011) 1.03
Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect (2011) 1.00
Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother (2011) 1.00
Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection. J Antimicrob Chemother (2009) 0.99
Effect of siliconized latex urinary catheters on the activity of carbapenems against Pseudomonas aeruginosa strains with defined mutations in ampC, oprD, and genes coding for efflux systems. Int J Antimicrob Agents (2003) 0.99
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother (2013) 0.97
Genetic variability among ampC genes from acinetobacter genomic species 3. Antimicrob Agents Chemother (2008) 0.97
Virulence profiles of bacteremic extended-spectrum β-lactamase-producing Escherichia coli: association with epidemiological and clinical features. PLoS One (2012) 0.97
Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. J Infect (2011) 0.95
[Infectious complications in 159 consecutive kidney transplant recipients]. Enferm Infecc Microbiol Clin (2009) 0.95
Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like. Int J Antimicrob Agents (2011) 0.95
Increased raw poultry meat colonization by extended spectrum beta-lactamase-producing Escherichia coli in the south of Spain. Int J Food Microbiol (2012) 0.94
Spanish multicenter study of the epidemiology and mechanisms of amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother (2012) 0.94
Prevalence of IS(Aba1) in epidemiologically unrelated Acinetobacter baumannii clinical isolates. FEMS Microbiol Lett (2007) 0.93
Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologica (2011) 0.93
Characterisation of clinical and food animal Escherichia coli isolates producing CTX-M-15 extended-spectrum β-lactamase belonging to ST410 phylogroup A. Int J Antimicrob Agents (2011) 0.92
[Prevalence of the tetA and tetB genes as mechanisms of resistance to tetracycline and minocycline in Acinetobacter baumannii clinical isolates]. Enferm Infecc Microbiol Clin (2006) 0.92
Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J Antimicrob Chemother (2005) 0.91
[Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica]. Enferm Infecc Microbiol Clin (2009) 0.91
Comparison of a repetitive extragenic palindromic sequence-based PCR method and clinical and microbiological methods for determining strain sources in cases of nosocomial Acinetobacter baumannii bacteremia. J Clin Microbiol (2002) 0.90
[In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010]. Enferm Infecc Microbiol Clin (2012) 0.90
Evaluation of the Etest method for fosfomycin susceptibility of ESBL-producing Klebsiella pneumoniae. J Antimicrob Chemother (2007) 0.89
"The 3/3 strategy": a successful multifaceted hospital wide hand hygiene intervention based on WHO and continuous quality improvement methodology. PLoS One (2012) 0.88
Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal. Medicine (Baltimore) (2014) 0.88
GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin (2011) 0.88
Analysis of plasmids encoding extended-spectrum beta-lactamases (ESBLs) from Escherichia coli isolated from non-hospitalised patients in Seville. Int J Antimicrob Agents (2007) 0.88
Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost. Antimicrob Agents Chemother (2012) 0.88
Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes. Medicine (Baltimore) (2011) 0.87